Cary Street Partners Financial LLC Buys 5,577 Shares of Merck & Co., Inc. $MRK

Posted by Brenda Bartman on May 26th, 2026

Cary Street Partners Financial LLC lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 2.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 206,848 shares of the company’s stock after purchasing an additional 5,577 shares during the quarter. Cary Street Partners Financial LLC’s holdings in Merck & Co., Inc. were worth $21,773,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MRK. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. in the 4th quarter worth about $25,000. United Financial Planning Group LLC purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter worth about $31,000. High Note Wealth LLC boosted its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the period. Tucker Asset Management LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $34,000. Finally, Wealth Watch Advisors INC purchased a new stake in Merck & Co., Inc. during the 3rd quarter valued at about $34,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Performance

MRK stock opened at $122.55 on Tuesday. The company has a market cap of $302.67 billion, a P/E ratio of 34.52, a price-to-earnings-growth ratio of 2.76 and a beta of 0.18. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock’s fifty day moving average price is $116.05 and its 200-day moving average price is $110.68. Merck & Co., Inc. has a 1 year low of $75.40 and a 1 year high of $125.14.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRK has been the subject of several research analyst reports. Citigroup initiated coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. Wells Fargo & Company decreased their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research report on Friday, February 13th. Barclays started coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective for the company. Finally, Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

Check Out Our Latest Report on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.